vs

Side-by-side financial comparison of Genius Sports Ltd (GENI) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

Real Brokerage Inc is the larger business by last-quarter revenue ($568.5M vs $510.9M, roughly 1.1× Genius Sports Ltd). Real Brokerage Inc runs the higher net margin — -0.1% vs -12.3%, a 12.3% gap on every dollar of revenue. Genius Sports Ltd produced more free cash flow last quarter ($69.6M vs $8.4M).

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

GENI vs REAX — Head-to-Head

Bigger by revenue
REAX
REAX
1.1× larger
REAX
$568.5M
$510.9M
GENI
Higher net margin
REAX
REAX
12.3% more per $
REAX
-0.1%
-12.3%
GENI
More free cash flow
GENI
GENI
$61.2M more FCF
GENI
$69.6M
$8.4M
REAX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GENI
GENI
REAX
REAX
Revenue
$510.9M
$568.5M
Net Profit
$-63.0M
$-447.0K
Gross Margin
25.2%
7.9%
Operating Margin
-11.5%
-0.1%
Net Margin
-12.3%
-0.1%
Revenue YoY
52.6%
Net Profit YoY
82.7%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENI
GENI
REAX
REAX
Q4 25
$510.9M
Q3 25
$335.4M
$568.5M
Q2 25
$215.2M
$540.7M
Q1 25
$119.7M
$354.0M
Q4 24
$413.0M
Q3 24
$285.8M
$372.5M
Q2 24
$184.1M
Q1 24
$97.2M
$200.7M
Net Profit
GENI
GENI
REAX
REAX
Q4 25
$-63.0M
Q3 25
$-447.0K
Q2 25
$-47.3M
$1.5M
Q1 25
$-25.5M
$-5.0M
Q4 24
$-85.5M
Q3 24
$-47.1M
$-2.6M
Q2 24
$-35.5M
Q1 24
$-25.2M
$-16.1M
Gross Margin
GENI
GENI
REAX
REAX
Q4 25
25.2%
Q3 25
24.2%
7.9%
Q2 25
19.1%
8.9%
Q1 25
10.7%
9.6%
Q4 24
16.7%
Q3 24
20.5%
8.6%
Q2 24
18.6%
Q1 24
9.8%
10.3%
Operating Margin
GENI
GENI
REAX
REAX
Q4 25
-11.5%
Q3 25
-15.3%
-0.1%
Q2 25
-21.0%
0.3%
Q1 25
-20.3%
-1.5%
Q4 24
-18.0%
Q3 24
-13.9%
-0.7%
Q2 24
-16.8%
Q1 24
-23.7%
-7.8%
Net Margin
GENI
GENI
REAX
REAX
Q4 25
-12.3%
Q3 25
-0.1%
Q2 25
-22.0%
0.3%
Q1 25
-21.3%
-1.4%
Q4 24
-20.7%
Q3 24
-16.5%
-0.7%
Q2 24
-19.3%
Q1 24
-25.9%
-8.0%
EPS (diluted)
GENI
GENI
REAX
REAX
Q4 25
Q3 25
$0.00
Q2 25
$0.01
Q1 25
$-0.02
Q4 24
Q3 24
$-0.01
Q2 24
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENI
GENI
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$280.6M
$38.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$724.5M
$53.6M
Total Assets
$1.1B
$145.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENI
GENI
REAX
REAX
Q4 25
$280.6M
Q3 25
$110.2M
$38.7M
Q2 25
$110.2M
$49.7M
Q1 25
$110.2M
$24.7M
Q4 24
$100.3M
Q3 24
$100.3M
$22.6M
Q2 24
$100.3M
Q1 24
$100.3M
$20.1M
Stockholders' Equity
GENI
GENI
REAX
REAX
Q4 25
$724.5M
Q3 25
$572.4M
$53.6M
Q2 25
$572.4M
$49.2M
Q1 25
$572.4M
$32.8M
Q4 24
$573.0M
Q3 24
$573.0M
$29.8M
Q2 24
$573.0M
Q1 24
$573.0M
$25.6M
Total Assets
GENI
GENI
REAX
REAX
Q4 25
$1.1B
Q3 25
$792.3M
$145.2M
Q2 25
$792.3M
$149.4M
Q1 25
$792.3M
$100.5M
Q4 24
$775.7M
Q3 24
$775.7M
$102.5M
Q2 24
$775.7M
Q1 24
$775.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENI
GENI
REAX
REAX
Operating Cash FlowLast quarter
$81.9M
$8.8M
Free Cash FlowOCF − Capex
$69.6M
$8.4M
FCF MarginFCF / Revenue
13.6%
1.5%
Capex IntensityCapex / Revenue
2.4%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$33.5M
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENI
GENI
REAX
REAX
Q4 25
$81.9M
Q3 25
$-4.8M
$8.8M
Q2 25
$-1.2M
$41.0M
Q1 25
$-14.6M
$15.9M
Q4 24
$14.9M
Q3 24
$-9.2M
$7.2M
Q2 24
Q1 24
$21.5M
Free Cash Flow
GENI
GENI
REAX
REAX
Q4 25
$69.6M
Q3 25
$-14.2M
$8.4M
Q2 25
$-5.8M
$40.8M
Q1 25
$-16.0M
$15.7M
Q4 24
$11.3M
Q3 24
$-11.6M
$6.8M
Q2 24
Q1 24
$21.4M
FCF Margin
GENI
GENI
REAX
REAX
Q4 25
13.6%
Q3 25
-4.2%
1.5%
Q2 25
-2.7%
7.5%
Q1 25
-13.4%
4.4%
Q4 24
2.7%
Q3 24
-4.1%
1.8%
Q2 24
Q1 24
10.7%
Capex Intensity
GENI
GENI
REAX
REAX
Q4 25
2.4%
Q3 25
2.8%
0.1%
Q2 25
2.1%
0.0%
Q1 25
1.2%
0.1%
Q4 24
0.9%
Q3 24
0.9%
0.1%
Q2 24
Q1 24
0.0%
Cash Conversion
GENI
GENI
REAX
REAX
Q4 25
Q3 25
Q2 25
27.13×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons